Drug intelligence / Profile preview

MEM-288 + nivolumab

Development stage: Unknown
Lead developer: Memgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral, Intravenous

Overview

MEM-288 + nivolumab is a combination therapy consisting of an oncolytic adenovirus (MEM-288) and an immune checkpoint inhibitor (nivolumab). MEM-288 is engineered to express interferon beta (IFNβ) and a membrane-stable version of CD40 ligand (MEM40), providing a triple mechanism of action: selective tumor cell destruction, immune stimulation via CD40 pathway activation, and antitumor effects of interferon. Nivolumab is a PD-1 inhibitor that prevents cancer cells from evading immune detection. The combination aims to generate synergistic antitumor immune responses, particularly in patients who have progressed on prior immunotherapy.

Targets

IFNAR (Immune system modulation via type I interferon receptor)CXADR (Coxsackievirus and adenovirus receptor)CD40 (Cluster of differentiation 40 receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on MEM-288 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEM-288 + nivolumab.

Explore the full profile